The Food and Drug Administration today  state-licensed pharmacists to prescribe Paxlovid (nirmatrelvir and ritonavir) to patients as a treatment for those at high risk of severe COVID-19. Because Paxlovid must be taken within five days of symptom onset, the change could spur expanded access and more-timely treatment of eligible patients. The change was made through an amended emergency use authorization. 

Related News Articles

Headline
The Centers for Disease Control and Prevention has added new resources for health care providers to its Be Ready for Measles Toolkit. They include a decision…
Headline
There have been 1,168 confirmed cases of measles across 33 states as of June 6 this year, according to the latest data from the Centers for Disease Control and…
Headline
A JAMA study published June 3 found that of 2,237 counties across the U.S., 78% reported declines in vaccination rates for measles, mumps and rubella from 2019…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
There have been 1,024 confirmed cases of measles across the U.S. so far in 2025, according to the latest data from the Centers for Disease Control and…
Headline
There have been 1,001 confirmed cases of measles across the U.S. so far in 2025, according to the latest data from the Centers for Disease Control and…